Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Felix Gonzalez-Torres' and Gregg Bordowitz’s works express their experiences of living through a pandemic and subsequent social change and draw out key human rights themes.
AMA J Ethics. 2020;22(9):E821-829. doi:
10.1001/amajethics.2020.821.
Focusing on social processes contributing to marginalization can help clinicians and policy makers mitigate food insecurity risk through improved patient-centered care.
AMA J Ethics. 2018;20(10):E941-947. doi:
10.1001/amajethics.2018.941.
Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
AMA J Ethics. 2019;21(9):E729-734. doi:
10.1001/amajethics.2019.729.
Global health outreach programs can risk benefitting students from resource-rich areas of the world more than the patients in resource-poor areas of the world. This month’s episode of Ethics Talk explores an alternative to academic health center-based health outreach programs.